Pegylated Interferon (PEG-IFN) alfa-2a

DRUG3 trials

Sponsors

Janssen Infectious Diseases BVBA, Hoffmann-La Roche

Conditions

Hepatitis C, ChronicHepatitis D, Chronic

Phase 2

Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection

CompletedNCT02716779

Hoffmann-La RocheHepatitis C, Chronic

Start: 2007-04-30End: 2010-04-30Updated: 2016-08-22

Phase 3

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

CompletedNCT01054573

Janssen Infectious Diseases BVBAHepatitis C, Chronic

Start: 2010-04-30End: 2012-05-31Updated: 2013-05-08

A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)

CompletedNCT02732639

Hoffmann-La RocheHepatitis D, Chronic

Start: 2005-10-31End: 2008-12-31Updated: 2016-08-26

Related Papers

Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir

Antimicrobial Agents and Chemotherapy2015-02-2613 citations

Treatment with Telaprevir/PEG-IFN/RBV after 14-day Telaprevir exposure in phase I studies: Results from the phase IIIB C219 rollover study

Zeitschrift für Gastroenterologie2013-08-161 citations